KRAS status was selected since, in the Consensus Molecular Subtype classification [33], CRC tumors are stratified in four groups and KRAS mutations are over-represented in the aggressive-upon-relapse CMS3 subtype. Here, KRAS is linked to colorectal carcinoma.